Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of erlotinib (Tarceva) and cetuximab (Erbitux) in advanced solid tumours, with emphasis on non small cell lung cancer (NSCLC).

Next Previous
X
Search
Trial Profile

Phase I/II study of erlotinib (Tarceva) and cetuximab (Erbitux) in advanced solid tumours, with emphasis on non small cell lung cancer (NSCLC).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use

    • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 09 May 2012 Actual patient number is 64 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top